Al-Mehdi: Rx of IBD Flashcards
pathogenesis behind IBD summed up
loss of tolerance of mucosal immune system leading to attack of one’s own microbiota
how are naiive Th0 (CD4) T cells activated
dendritic cells present antigen
co-stimulation from CD80/86 binding to CD28
activation of T cell allows for what to be produced and what effect
IL-2; clonal expansion of T cells
normally, _____ takes off phosphate group of NFAT when influx of Ca2+ binds to calmodulin in T cell
calcineurin
what happens when IL-2 autocrine signaling happens in T cell
activates mTOR, cytokines produced, clonal expansion of cells
cytokine that activates Th1 cell
IL-12
T cell that activates macrophages and CD8+ T cells
Th1
cytokines that activate Th17 T cell
IL-1, 6, 23
this T cell attracts neutrophils to infection site
Th17
T cells involved in Crohn’s disease
Th1 and Th17
cytokines that activate Th2 T cell
IL-4, IL-25
cytokine that Th2 cell makes that activates eosinophils
IL-5
cytokine that Th2 cell makes that activates mast cells
IL-9
cytokines from Th2 T cell involved in elimination of helminths, atopy, eosinophilic esophagitis
IL-5 and IL-9
T cell involved in Ulcerative colitis
Th2
cytokine that activates Treg cell
IFN-a
T cell that produces IL-10 and TGF-b to prevent autoimmune disease and inflammation
Treg
cytokines that activate Tfh (T follicular helper cell)
IL-4, IL-21
T cell that produces IL-21 that activates B cells
Tfh (T follicular helper) cell
Which T cell and which cytokines reduce inflammation and disease severity in autoimmune diseases?
Treg; IL-10 and TGF-beta
drugs that block lymphocyte egress from lymph nodes and peyer’s patches (used for UC)
OZANIMOD
FINGOLIMOD
(-IMODs)
these drugs are irreversible agonists of sphingosine-1-phosphate receptor (block lymphocyte egress)
OZANIMOD
FINGOLIMOD
drugs used for UC and CD that block lymphocyte transmigration out of endothelium and their MoA
VEDOLIZUMAB
ETROLIZUMAB
(-LIZUMABs)
MoA: anti-a4b7 in the gut
integrin on lymphocyte that VEDOLIZUMAB and ETROLIZUMAB block
a4b7